Hypoxia and metabolic adaptation of cancer cells

Oncogenesis

Volumn 5, Issue 1, 2016, Pages

  Eales, K L ^a   Hollinshead, K E R ^a   Tennant, D A ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85119301268     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/ONCSIS.2015.50     Document Type: Review

References (107)

1. Yu B, Shah A, Wang B, Rajaram N, Wang Q, Ramanujam N et al. Measuring tumor cycling hypoxia and angiogenesis using a side‐firing fiber optic probe. J Biophotonics 2014; 7: 552–564.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249–257.
3. Dunwoodie SL. The role of hypoxia in development of the mammalian embryo. Dev Cell 2009; 17: 755–773.
4. Jungermann K, Kietzmann T. Oxygen: modulator of metabolic zonation and disease of the liver. Hepatology 2000; 31: 255–260.
5. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmac Sci 2012; 33: 207–214.
6. Goldmann E. The growth of malignant disease in man and the lower animals, with special reference to the vascular system. Proc R Soc Med 1908; 1: 1–13.
7. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/ vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999; 237: 97–132.
8. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000; 156: 1363–1380.
9. Dang CV, Hamaker M, Sun P, Le A, Gao P. Therapeutic targeting of cancer cell metabolism. J Mol Med 2011; 89: 205–212.
10. Dewhirst MW. Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res 2009; 172: 653–665.
11. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008; 8: 425–437.
12. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107: 43–54.
13. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294: 1337–1340.
14. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271–275.
15. Berra E, Roux D, Richard DE, Pouyssegur J. Hypoxia-inducible factor-1 alpha (HIF-1 alpha) escapes O(2)-driven proteasomal degradation irrespective of its subcellular localization: nucleus or cytoplasm. EMBO Rep 2001; 2: 615–620.
16. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510–5514.
17. Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 1996; 271: C1172–C1180.
18. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002; 16: 1466–1471.
19. McNeill LA, Hewitson KS, Claridge TD, Seibel JF, Horsfall LE, Schofield CJ. Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. Biochem J 2002; 367: 571–575.
20. Dayan F, Roux D, Brahimi-Horn MC, Pouyssegur J, Mazure NM. The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Res 2006; 66: 3688–3698.
21. Koivunen P, Hirsila M, Gunzler V, Kivirikko KI, Myllyharju J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem 2004; 279: 9899–9904.
22. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996; 271: 17771–17778.
23. Schodel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 2011; 117: e207–e217.
24. Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007; 26: 281–290.
25. Shah T, Krishnamachary B, Wildes F, Mironchik Y, Kakkad S, Jacob D et al. HIF isoforms have divergent effects on invasion, metastasis, metabolism and formation of lipid droplets. Oncotarget 2015; 6: 28104–28119.
26. Luo W, Semenza GL. Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget 2011; 2: 551.
27. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012; 148: 399–408.
28. Wiesener MS, Jurgensen JS, Rosenberger C, Scholze CK, Horstrup JH, Warnecke C et al. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 2003; 17: 271–273.
29. Tennant DA, Duran RV, Boulahbel H, Gottlieb E. Metabolic transformation in cancer. Carcinogenesis 2009; 30: 1269–1280.
30. Ginouves A, Ilc K, Macias N, Pouyssegur J, Berra E. PHDs overactivation during chronic hypoxia "desensitizes" HIFalpha and protects cells from necrosis. Proc Natl Acad Sci USA 2008; 105: 4745–4750.
31. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J HIF. prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 2003; 22: 4082–4090.
32. Semenza G (ed). Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harb Symp Quant Biol 2011; 76: 347–353.
33. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical out-come. Cancer Metastasis Rev 2007; 26: 225–239.
34. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 2013; 123: 3664.
35. Hutchison GJ, Valentine HR, Loncaster JA, Davidson SE, Hunter RD, Roberts SA et al. Hypoxia-inducible factor 1α expression as an intrinsic marker of hypoxia correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res 2004; 10: 8405–8412.
36. Mayer A, Wree A, Höckel M, Leo C, Pilch H, Vaupel P. Lack of correlation between expression of HIF-1α protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. Cancer Res 2004; 64: 5876–5881.
37. Hammond EM, Giaccia AJ. The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun 2005; 331: 718–725.
38. Schmid T, Zhou J, Brune B. HIF-1 and p53: communication of transcription factors under hypoxia. J Cell Mol Med 2004; 8: 423–431.
39. Hammond EM, Denko NC, Dorie MJ, Abraham RT, Giaccia AJ. Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol 2002; 22: 1834–1843.
40. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000; 16: 653–699.
41. Baudino TA, Cleveland JL. The Max network gone mad. Mol Cell Biol 2001; 21: 691–702.
42. Corn PG, Ricci MS, Scata KA, Arsham AM, Simon MC, Dicker DT et al. Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol Ther 2005; 4: 1285–1294.
43. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007; 11: 335–347.
44. Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer 2008; 8: 51–56.
45. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shut-tling. Genes Dev 2008; 22: 239–251.
46. Advani SH. Targeting mTOR pathway: a new concept in cancer therapy. Indian J Med Paediatr Oncol 2010; 31: 132–136.
47. Pistollato F, Rampazzo E, Persano L, Abbadi S, Frasson C, Denaro L et al. Interaction of hypoxia-inducible factor-1alpha and Notch signaling regulates medulloblastoma precursor proliferation and fate. Stem Cells 2010; 28: 1918–1929.
48. Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002; 99: 3398–3403.
49. Pescador N, Villar D, Cifuentes D, Garcia-Rocha M, Ortiz-Barahona A, Vazquez S et al. Hypoxia promotes glycogen accumulation through hypoxia inducible factor (HIF)-mediated induction of glycogen synthase 1. PLoS ONE 2010; 5: e9644.
50. Gatenby RA, Gawlinski ET. Mathematical models of tumour invasion mediated by transformation-induced alteration of microenvironmental pH. Novartis Found Symp 2001; 240: 85–96; Discussion–9.
51. Favaro E, Bensaad K, Chong MG, Tennant DA, Ferguson DJ, Snell C et al. Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab 2012; 16: 751–764.
52. Obel LF, Muller MS, Walls AB, Sickmann HM, Bak LK, Waagepetersen HS et al. Brain glycogen-new perspectives on its metabolic function and regulation at the subcellular level. Front Neuroenergetics 2012; 4: 3.
53. Favaro E, Harris AL. Targeting glycogen metabolism: a novel strategy to inhibit cancer cell growth? Oncotarget 2013; 4: 3–4.
54. Chance B, Williams GR. Respiratory enzymes in oxidative phosphorylation. III. The steady state. J BIol Chem 1955; 217: 409–427.
55. Mayevsky A. Brain NADH redox state monitored in vivo by fiber optic surface fluorometry. Brain Res 1984; 319: 49–68.
56. Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 2006; 281: 9030–9037.
57. Gatenby RA, Gawlinski ET. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res 2003; 63: 3847–3854.
58. Markert CL, Appella E. Physicochemical nature of isozvmes. Ann N Y Acad Sci 1961; 94: 678–690.
59. Cahn RD, Zwilling E, Kaplan NO, Levine L. Nature and development of lactic dehydrogenases: the two major types of this enzyme form molecular hybrids which change in makeup during development. Science 1962; 136: 962–969.
60. Bishop MJ, Everse J, Kaplan NO. Identification of lactate-dehydrogenase Iso-enzymes by rapid Kinetics. Proc Natl Acad Sci USA 1972; 69: 1761–1765.
61. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehy-drogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996; 271: 32529–32537.
62. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004; 5: 343–354.
63. Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, Semenza GL. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 2007; 129: 111–122.
64. Semenza GL. Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem J 2007; 405: 1–9.
65. Fan J, Ye J, Kamphorst JJ, Shlomi T, Thompson CB, Rabinowitz JD. Quantitative flux analysis reveals folate-dependent NADPH production. Nature 2014; 510: 298–302.
66. Lewis CA, Parker SJ, Fiske BP, McCloskey D, Gui DY, Green CR et al. Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells. Mol Cell 2014; 55: 253–263.
67. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G et al. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005; 65: 177–185.
68. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126: 107–120.
69. Kennedy FG, Jones DP. Oxygen dependence of mitochondrial function in iso-lated rat cardiac myocytes. Am J Physiol 1986; 250: C374–C383.
70. Wilson DF, Rumsey WL, Green TJ, Vanderkooi JM. The oxygen dependence of mitochondrial oxidative phosphorylation measured by a new optical method for measuring oxygen concentration. J Biol Chem 1988; 263: 2712–2718.
71. Kaplon J, Zheng L, Meissl K, Chaneton B, Selivanov VA, Mackay G et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 2013; 498: 109–112.
72. Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, Mates JM et al. Pyruvate car-boxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci USA 2011; 108: 8674–8679.
73. Cardaci S, Zheng L, MacKay G, van den Broek NJ, MacKenzie ED, Nixon C et al. Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. Nat Cell Biol 2015; 17: 1317–1326.
74. Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydra-tase. Nature 2011; 477: 225–228.
75. Lussey-Lepoutre C, Hollinshead KE, Ludwig C, Menara M, Morin A, Castro-Vega LJ et al. Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism. Nat Commun 2015; 6: 8784.
76. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 2008; 105: 18782–18787.
77. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009; 15: 6479–6483.
78. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 2012; 15: 110–121.
79. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2012; 481: 385–388.
80. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O et al. p53 regulates mitochondrial respiration. Science 2006; 312: 1650–1653.
81. Filipp FV, Scott DA, Ronai ZA, Osterman AL, Smith JW. Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigm Cell Melanoma R 2012; 25: 375–383.
82. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2012; 481: 380–384.
83. Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, Sachdeva UM et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci USA 2011; 108: 19611–19616.
84. Yoo H, Antoniewicz MR, Stephanopoulos G, Kelleher JK. Quantifying reductive carboxylation flux of glutamine to lipid in a brown adipocyte cell line. J BIol Chem 2008; 283: 20621–20627.
85. Fendt SM, Bell EL, Keibler MA, Olenchock BA, Mayers JR, Wasylenko TM et al. Reductive glutamine metabolism is a function of the alpha-ketoglutarate to citrate ratio in cells. Nat Commun 2013; 4: 2236.
86. Gameiro PA, Yang JJ, Metelo AM, Perez-Carro R, Baker R, Wang ZW et al. In vivo HIF-mediated reductive carboxylation Is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab 2013; 17: 372–385.
87. Sun RC, Denko NC. Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab 2014; 19: 285–292.
88. Mullen AR, Hu Z, Shi X, Jiang L, Boroughs LK, Kovacs Z et al. Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mito-chondrial defects. Cell Rep 2014; 7: 1679–1690.
89. Gardner PR. Aconitase: sensitive target and measure of superoxide. Methods Enzymol 2002; 349: 9–23.
90. Grassian AR, Parker S, Davidson S, Divakaruni A, Green C, Zhang XM et al. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxi-dative mitochondrial metabolism. Cancer Res 2014; 74: 3317–3331.
91. Beinert H, Kennedy MC, Stout CD. Aconitase as ironminus signSulfur protein, enzyme, and iron-regulatory protein. Chem Rev 1996; 96: 2335–2374.
92. Dupuy J, Volbeda A, Carpentier P, Darnault C, Moulis JM, Fontecilla-Camps JC. Crystal structure of human iron regulatory protein 1 as cytosolic aconitase. Structure 2006; 14: 129–139.
93. Walden WE, Selezneva AI, Dupuy J, Volbeda A, Fontecilla-Camps JC, Theil EC et al. Structure of dual function iron regulatory protein 1 complexed with ferritin IRE-RNA. Science 2006; 314: 1903–1908.
94. Hentze MW, Caughman SW, Rouault TA, Barriocanal JG, Dancis A, Harford JB et al. Identification of the iron-responsive element for the translational regulation of human ferritin mRNA. Science 1987; 238: 1570–1573.
95. Koeller DM, Casey JL, Hentze MW, Gerhardt EM, Chan LN, Klausner RD et al. A cytosolic protein binds to structural elements within the iron regulatory region of the transferrin receptor mRNA. Proc Natl Acad Sci USA 1989; 86: 3574–3578.
96. Fan J, Kamphorst JJ, Mathew R, Chung MK, White E, Shlomi T et al. Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol Syst Biol 2013; 9: 712.
97. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007; 104: 19345–19350.
98. Jiang P, Du W, Mancuso A, Wellen KE, Yang X. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature 2013; 493: 689–693.
99. Kamphorst JJ, Chung MK, Fan J, Rabinowitz JD. Quantitative analysis of acetyl-CoA production in hypoxic cancer cells reveals substantial contribution from acetate. Cancer Metab 2014; 2: 23.
100. Schug ZT, Peck B, Jones DT, Zhang Q, Grosskurth S, Alam IS et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell 2015; 27: 57–71.
101. Anderson KA, Hirschey MD. Mitochondrial protein acetylation regulates meta-bolism. Essays Biochem 2012; 52: 23–35.
102. Frezza C, Zheng L, Tennant DA, Papkovsky DB, Hedley BA, Kalna G et al. Metabolic profiling of hypoxic cells revealed a catabolic signature required for cell survival. PLoS ONE 2011; 6: e24411.
103. Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 2013; 497: 633–637.
104. Kamphorst JJ, Cross JR, Fan J, de Stanchina E, Mathew R, White EP et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci USA 2013; 110: 8882–8887.
105. De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantelmo AR et al. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 2013; 154: 651–663.
106. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008; 118: 3930–3942.
107. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010; 10: 267–277.